Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Deals

Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal

Fineline Cube Jan 22, 2026
Company Deals

Insilico Licenses NLRP3 Inhibitor ISM8969 to Hengtai in $64M CNS Drug Deal

Fineline Cube Jan 20, 2026
Company Deals

Shionogi Boosts ViiV Stake to 21.7% in $2.1 Billion Deal, Doubles Down on HIV Focus

Fineline Cube Jan 20, 2026
Company Deals Medical Device

EasyDiagnosis Bio to Acquire 51% of Ailex Medical in $5.1M Deal, Gains IVD Platform

Fineline Cube Jan 20, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Deals

MindRank Ltd Secures Over $20 Million in Series A+ Funding to Advance AI Drug Development

Fineline Cube Jul 19, 2023

China-based artificial intelligence (AI)-enabled drug developer MindRank Ltd has reportedly secured more than USD 20...

Company Deals

Zhejiang Dian Diagnostics Partners with Northeast Infectious Diseases Alliance to Enhance Surveillance

Fineline Cube Jul 19, 2023

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics specialist based in China, has...

Company Deals

Novartis Acquires DTx Pharma and Its FALCON Technology for Up to $1 Billion

Fineline Cube Jul 19, 2023

Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced the acquisition of DTx Pharma Inc., a...

Company Deals

Allen Institute for Immunology Partners with Eli Lilly to Study Atopic Dermatitis and Rheumatoid Arthritis

Fineline Cube Jul 19, 2023

The US-based Allen Institute for Immunology has announced a strategic partnership with compatriot company Eli...

Company Deals

Pfizer and Flagship Pioneering Invest $100 Million in Drug Candidates Development

Fineline Cube Jul 19, 2023

Global pharmaceutical giant Pfizer (NYSE: PFE) and venture capital firm Flagship Pioneering have this week...

Company Drug

Qihan Biotech’s QN-019a Receives Clinical Clearance for Gene-Edited iPSC-Derived Cell Therapy in China

Fineline Cube Jul 19, 2023

Hangzhou Qihan Biotech Co., Ltd., a leading specialist in xenotransplantation based in China, has announced...

Company Deals

Major Pharma Companies Pledge Support for 250,000 Genomes Sequencing Project

Fineline Cube Jul 19, 2023

This week, leading pharmaceutical companies AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), AstraZeneca (AZ; NASDAQ: AZN),...

Company Deals

Sumitomo Pharma to Invest $30 Million in China for New Product Development

Fineline Cube Jul 19, 2023

Japan-based Sumitomo Pharma (TYO: 4506), through its China unit, is planning a significant investment of...

Company Drug

Antengene Initiates Phase I ERASER Study for ATG-017 in Combination with Nivolumab

Fineline Cube Jul 19, 2023

China-based biopharmaceutical company Antengene Corp., Ltd (HKG: 6996) has announced the first patient dosing in...

Company Drug

Sichuan Huiyu Pharmaceutical’s KRAS G12C Drug HYP-2090PTSA Accepted for NMPA Review

Fineline Cube Jul 19, 2023

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that the...

Company Deals Medical Device

Puncture Robotic Secures $13.9 Million in Series A+ Funding to Advance Medical Robotics

Fineline Cube Jul 19, 2023

Puncture Robotic, a Shanghai-based developer of medical robots, has reportedly raised RMB 100 million (USD...

Company Drug

Sanofi and AstraZeneca Receive FDA Approval for RSV Prevention Treatment Beyfortus

Fineline Cube Jul 18, 2023

France-based Sanofi (NASDAQ: SNY) has announced that it, along with AstraZeneca (AZ; NASDAQ: AZN), has...

Drug Policy / Regulatory

NMPA Releases 70th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube Jul 18, 2023

The National Medical Products Administration (NMPA) has released the 70th batch of reference drugs for...

Company Deals

Cutia Therapeutics’ CU-40101 Completes Phase I Clinical Trial for Androgenetic Alopecia

Fineline Cube Jul 18, 2023

Cutia Therapeutics (HKG: 2487), a developer of dermatology therapies, has announced the completion of the...

Company Drug

Mabwell Bioscience’s 7MW3711 ADC for B7-H3 Gets Clinical Trial Approval in China

Fineline Cube Jul 18, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced receiving clinical...

Company Drug

Bayer’s Kerendia Officially Launched in China for Type 2 Diabetes-Related CKD

Fineline Cube Jul 18, 2023

German pharmaceutical giant Bayer’s (ETR: BAYN) Kerendia (finerenone), the first nonsteroidal, selective mineralocorticoid receptor (MR)...

Company Deals

Sensview Secures Tens of Millions in Series A+ Funding for X-Ray Detector Tech

Fineline Cube Jul 18, 2023

Sensview, a developer of solid-state imaging chips and detector module products based in Chengdu, has...

Company Deals

Nanjing Enrui Kainuo Biotechnology Secures Pre-Series A Funding for Cell Therapy Development

Fineline Cube Jul 18, 2023

Nanjing Enrui Kainuo Biotechnology Co., Ltd, a China-based cell therapy developer, has reportedly raised tens...

Company Drug

Shenzhen Salubris Pharmaceuticals Receives FDA Clearance for SAL0119 Clinical Trial

Fineline Cube Jul 18, 2023

Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294), a Chinese pharmaceutical company, has announced that it...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for CTLA-4 and PD-1 Inhibitor Combo Study

Fineline Cube Jul 18, 2023

China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that it has received approval from China’s...

Posts pagination

1 … 447 448 449 … 612

Recent updates

  • Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal
  • Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors
  • Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific
  • Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback
  • Eyebright Medical to Acquire Control of Delta Medical in $143 M Sports‑Medicine Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Company Drug

Biokin’s Iza-bren ADC Receives NMPA Filing Acceptance for ESCC, World’s First EGFR×HER3 Bispecific

Company Drug

Kawin Technology Withdraws Hepatitis B Filing for Peginterferon Alfacon‑2 After NMPA Feedback

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.